Related Experiment Video
Updated: Mar 24, 2026
04:11
Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection
Published on: December 15, 2023
5.1K
[Drug-resistant mutations in hepatitis B virus found in chronic HBV carriers using PCR sequencing technology]
1Tianjin Institute of Hepatology, Tianjin Second People's Hospital, Tianjin 300192, China.
Summary
This study identified drug-resistant mutations in hepatitis B virus (HBV) among chronic carriers receiving nucleos(t)ide analogues (NAs). Genotype C was predominant, and no significant difference in drug resistance was observed across HBV genotypes.
Area of Science:
- Hepatology
- Virology
- Molecular Biology
Background:
- Chronic hepatitis B virus (HBV) infection affects millions globally.
- Nucleos(t)ide analogues (NAs) are standard treatment for chronic HBV.
- Emergence of drug-resistant mutations (DRMs) can compromise treatment efficacy.
Purpose of the Study:
- To investigate drug-resistant mutations (DRMs) and genotypes of hepatitis B virus (HBV) in chronic HBV carriers.
- To analyze the prevalence of specific DRMs associated with different NA therapies.
- To assess the relationship between HBV genotypes and the occurrence of DRMs.
Main Methods:
- Recruitment of 317 chronic HBV carriers receiving NAs for at least three months.
- Detection of DRMs using Polymerase Chain Reaction (PCR) followed by sequencing.
- Statistical analysis of mutation data and HBV genotypes using SPSS21.0.
Main Results:
- DRMs were detected in 119 out of 317 patients (37.5%).
- Specific dominant mutational profiles were identified for lamivudine (LAM), adefovir (ADV), entecavir (ETV), telbivudine (LdT), and sequential/combined NA therapies.
- HBV genotype C was predominant (90.6%), followed by genotype B (8.8%) and genotype D (0.6%).
- No statistically significant difference in DRMs was found across different HBV genotypes (P > 0.05).
- Two tenofovir disoproxil fumarate (TDF)-resistant mutations (rtA194T) were identified.
Conclusions:
- The study provides updated information on NA-DRMs and HBV genotypes in chronic HBV carriers.
- Findings have potential clinical implications for managing HBV drug resistance.
- The study confirmed the presence of the TDF-associated mutation rtA194T.
Related Concept Videos
01:25Hepatitis
29
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
29
01:29Viruses with RNA Genomes
1.2K
RNA viruses are categorized into positive-strand, negative-strand, or double-stranded groups based on their genomic structure and replication mechanisms. This classification dictates how they exploit host cellular machinery for protein synthesis and replication. Some RNA viruses also utilize reverse transcription as part of their life cycle, further diversifying their replication strategies.Positive-Strand RNA VirusesPositive-strand RNA viruses have genomes that function directly as messenger...
1.2K
00:36Viral Mutations
40.7K
A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material...
40.7K